Targeting KRAS mutated non-small cell lung cancer: a history of failures and a future of hope for a diverse entity
Highlights • KRAS mutations are the most common genetic event in lung adenocarcinoma. • The prognostic and predictive value of KRAS mutations is unclear. • Previous attempts to directly target KRAS have been unsuccessful. • A large number of novel agents and combinations are being currently evaluate...
Gespeichert in:
| Veröffentlicht in: | Critical reviews in oncology/hematology 2017-02, Vol.110, p.1-12 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 12 |
|---|---|
| container_issue | |
| container_start_page | 1 |
| container_title | Critical reviews in oncology/hematology |
| container_volume | 110 |
| creator | Matikas, Alexios Mistriotis, Dimitrios Georgoulias, Vasilios Kotsakis, Athanasios |
| description | Highlights • KRAS mutations are the most common genetic event in lung adenocarcinoma. • The prognostic and predictive value of KRAS mutations is unclear. • Previous attempts to directly target KRAS have been unsuccessful. • A large number of novel agents and combinations are being currently evaluated |
| doi_str_mv | 10.1016/j.critrevonc.2016.12.005 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_swepu</sourceid><recordid>TN_cdi_swepub_primary_oai_swepub_ki_se_499609</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1040842816303675</els_id><sourcerecordid>1861594699</sourcerecordid><originalsourceid>FETCH-LOGICAL-c533t-e4b6b3f9b7de9b388f1865ec022347bc11d5fae93d41bca5f4616e3649cfec8b3</originalsourceid><addsrcrecordid>eNqNUk1v1DAQtRCIloW_gHzkkmDHjhNzQCpV-RCVkGg5W44zbr1N7MV2Fu2_x9EuReLExZ6PNzOa9wYhTElNCRVvt7WJLkfYB2_qpkRq2tSEtE_QOe07WREu6NNiE06qnjf9GXqR0pYQwrnonqOzpqdEMinPUbzV8Q6y83f46_eLGzwvWWcYsQ--SrOeJmygPNNSAEZ7A_Ed1vjepRziAQeLrXbTEiFh7ceSsUsu3pq4DzvANsQSHN0eYgIMPrt8eImeWT0leHX6N-jHx6vby8_V9bdPXy4vrivTMpYr4IMYmJVDN4IcWN9b2osWDGkaxrvBUDq2VoNkI6eD0a0tOwtggktjwfQD26Dq2Df9gt0yqF10s44HFbRTp9BDsUBxKUWhY4PeHPG7GH4ukLKaXVq31x7CklQZT1vJhVyh_RFqYkgpgn1sTolaFVJb9VchtSqkaKOKQqX09WnKMswwPhb-kaQAPhwBULjZO4gqGQeF-dFFMFmNwf3PlPf_NDGT887o6QEOkLZhib5wr6hKpUDdrJeyHgoVjDDRtew3XN--EA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1861594699</pqid></control><display><type>article</type><title>Targeting KRAS mutated non-small cell lung cancer: a history of failures and a future of hope for a diverse entity</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Matikas, Alexios ; Mistriotis, Dimitrios ; Georgoulias, Vasilios ; Kotsakis, Athanasios</creator><creatorcontrib>Matikas, Alexios ; Mistriotis, Dimitrios ; Georgoulias, Vasilios ; Kotsakis, Athanasios</creatorcontrib><description>Highlights • KRAS mutations are the most common genetic event in lung adenocarcinoma. • The prognostic and predictive value of KRAS mutations is unclear. • Previous attempts to directly target KRAS have been unsuccessful. • A large number of novel agents and combinations are being currently evaluated</description><identifier>ISSN: 1040-8428</identifier><identifier>EISSN: 1879-0461</identifier><identifier>DOI: 10.1016/j.critrevonc.2016.12.005</identifier><identifier>PMID: 28109399</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Animals ; Carcinoma, Non-Small-Cell Lung - drug therapy ; Carcinoma, Non-Small-Cell Lung - genetics ; Hematology, Oncology and Palliative Medicine ; Humans ; KRAS ; Lung Neoplasms - drug therapy ; Lung Neoplasms - genetics ; MEK ; Mutation ; NSCLC ; Predictive ; Prognosis ; Prognostic ; Proto-Oncogene Proteins p21(ras) - genetics ; Targeted therapy</subject><ispartof>Critical reviews in oncology/hematology, 2017-02, Vol.110, p.1-12</ispartof><rights>2016 Elsevier Ireland Ltd</rights><rights>Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c533t-e4b6b3f9b7de9b388f1865ec022347bc11d5fae93d41bca5f4616e3649cfec8b3</citedby><cites>FETCH-LOGICAL-c533t-e4b6b3f9b7de9b388f1865ec022347bc11d5fae93d41bca5f4616e3649cfec8b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.critrevonc.2016.12.005$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,778,782,883,3539,27911,27912,45982</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28109399$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttp://kipublications.ki.se/Default.aspx?queryparsed=id:135165835$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>Matikas, Alexios</creatorcontrib><creatorcontrib>Mistriotis, Dimitrios</creatorcontrib><creatorcontrib>Georgoulias, Vasilios</creatorcontrib><creatorcontrib>Kotsakis, Athanasios</creatorcontrib><title>Targeting KRAS mutated non-small cell lung cancer: a history of failures and a future of hope for a diverse entity</title><title>Critical reviews in oncology/hematology</title><addtitle>Crit Rev Oncol Hematol</addtitle><description>Highlights • KRAS mutations are the most common genetic event in lung adenocarcinoma. • The prognostic and predictive value of KRAS mutations is unclear. • Previous attempts to directly target KRAS have been unsuccessful. • A large number of novel agents and combinations are being currently evaluated</description><subject>Animals</subject><subject>Carcinoma, Non-Small-Cell Lung - drug therapy</subject><subject>Carcinoma, Non-Small-Cell Lung - genetics</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Humans</subject><subject>KRAS</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Lung Neoplasms - genetics</subject><subject>MEK</subject><subject>Mutation</subject><subject>NSCLC</subject><subject>Predictive</subject><subject>Prognosis</subject><subject>Prognostic</subject><subject>Proto-Oncogene Proteins p21(ras) - genetics</subject><subject>Targeted therapy</subject><issn>1040-8428</issn><issn>1879-0461</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNUk1v1DAQtRCIloW_gHzkkmDHjhNzQCpV-RCVkGg5W44zbr1N7MV2Fu2_x9EuReLExZ6PNzOa9wYhTElNCRVvt7WJLkfYB2_qpkRq2tSEtE_QOe07WREu6NNiE06qnjf9GXqR0pYQwrnonqOzpqdEMinPUbzV8Q6y83f46_eLGzwvWWcYsQ--SrOeJmygPNNSAEZ7A_Ed1vjepRziAQeLrXbTEiFh7ceSsUsu3pq4DzvANsQSHN0eYgIMPrt8eImeWT0leHX6N-jHx6vby8_V9bdPXy4vrivTMpYr4IMYmJVDN4IcWN9b2osWDGkaxrvBUDq2VoNkI6eD0a0tOwtggktjwfQD26Dq2Df9gt0yqF10s44HFbRTp9BDsUBxKUWhY4PeHPG7GH4ukLKaXVq31x7CklQZT1vJhVyh_RFqYkgpgn1sTolaFVJb9VchtSqkaKOKQqX09WnKMswwPhb-kaQAPhwBULjZO4gqGQeF-dFFMFmNwf3PlPf_NDGT887o6QEOkLZhib5wr6hKpUDdrJeyHgoVjDDRtew3XN--EA</recordid><startdate>20170201</startdate><enddate>20170201</enddate><creator>Matikas, Alexios</creator><creator>Mistriotis, Dimitrios</creator><creator>Georgoulias, Vasilios</creator><creator>Kotsakis, Athanasios</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>ADTPV</scope><scope>AOWAS</scope></search><sort><creationdate>20170201</creationdate><title>Targeting KRAS mutated non-small cell lung cancer: a history of failures and a future of hope for a diverse entity</title><author>Matikas, Alexios ; Mistriotis, Dimitrios ; Georgoulias, Vasilios ; Kotsakis, Athanasios</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c533t-e4b6b3f9b7de9b388f1865ec022347bc11d5fae93d41bca5f4616e3649cfec8b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Animals</topic><topic>Carcinoma, Non-Small-Cell Lung - drug therapy</topic><topic>Carcinoma, Non-Small-Cell Lung - genetics</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Humans</topic><topic>KRAS</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Lung Neoplasms - genetics</topic><topic>MEK</topic><topic>Mutation</topic><topic>NSCLC</topic><topic>Predictive</topic><topic>Prognosis</topic><topic>Prognostic</topic><topic>Proto-Oncogene Proteins p21(ras) - genetics</topic><topic>Targeted therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Matikas, Alexios</creatorcontrib><creatorcontrib>Mistriotis, Dimitrios</creatorcontrib><creatorcontrib>Georgoulias, Vasilios</creatorcontrib><creatorcontrib>Kotsakis, Athanasios</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>SwePub</collection><collection>SwePub Articles</collection><jtitle>Critical reviews in oncology/hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Matikas, Alexios</au><au>Mistriotis, Dimitrios</au><au>Georgoulias, Vasilios</au><au>Kotsakis, Athanasios</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Targeting KRAS mutated non-small cell lung cancer: a history of failures and a future of hope for a diverse entity</atitle><jtitle>Critical reviews in oncology/hematology</jtitle><addtitle>Crit Rev Oncol Hematol</addtitle><date>2017-02-01</date><risdate>2017</risdate><volume>110</volume><spage>1</spage><epage>12</epage><pages>1-12</pages><issn>1040-8428</issn><eissn>1879-0461</eissn><abstract>Highlights • KRAS mutations are the most common genetic event in lung adenocarcinoma. • The prognostic and predictive value of KRAS mutations is unclear. • Previous attempts to directly target KRAS have been unsuccessful. • A large number of novel agents and combinations are being currently evaluated</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>28109399</pmid><doi>10.1016/j.critrevonc.2016.12.005</doi><tpages>12</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1040-8428 |
| ispartof | Critical reviews in oncology/hematology, 2017-02, Vol.110, p.1-12 |
| issn | 1040-8428 1879-0461 |
| language | eng |
| recordid | cdi_swepub_primary_oai_swepub_ki_se_499609 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
| subjects | Animals Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics Hematology, Oncology and Palliative Medicine Humans KRAS Lung Neoplasms - drug therapy Lung Neoplasms - genetics MEK Mutation NSCLC Predictive Prognosis Prognostic Proto-Oncogene Proteins p21(ras) - genetics Targeted therapy |
| title | Targeting KRAS mutated non-small cell lung cancer: a history of failures and a future of hope for a diverse entity |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T02%3A33%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_swepu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Targeting%20KRAS%20mutated%20non-small%20cell%20lung%20cancer:%20a%20history%20of%20failures%20and%20a%20future%20of%20hope%20for%20a%20diverse%20entity&rft.jtitle=Critical%20reviews%20in%20oncology/hematology&rft.au=Matikas,%20Alexios&rft.date=2017-02-01&rft.volume=110&rft.spage=1&rft.epage=12&rft.pages=1-12&rft.issn=1040-8428&rft.eissn=1879-0461&rft_id=info:doi/10.1016/j.critrevonc.2016.12.005&rft_dat=%3Cproquest_swepu%3E1861594699%3C/proquest_swepu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1861594699&rft_id=info:pmid/28109399&rft_els_id=S1040842816303675&rfr_iscdi=true |